==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1234 details
Primary information
ThPP IDTh1032
Therapeutic Peptide/Protein NameCoagulation factor VIIa
SequenceANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQC view full sequnce in fasta
Functional ClassificationIb
Molecular Weight45079.1
Chemical FormulaC1972H3076N560O597S28
Isoelectric Point6.09
Hydrophobicity-0.311
Melting Point (℃)58
Half LifeN.A.
DescriptionRecombinant human coagulation Factor VIIa is intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues, cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication/DiseaseFor treatment of hemorrhagic complications in hemophilia A and B.
PharmacodynamicsTo treat bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.
Mechanism of ActionNovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of Distribution121 ± 30 mL/kg [adults]
Clearance33 - 37 mL/h x kg [healthy]
CategoriesCoagulants
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionAutoplex T (anti-inhibitor coagulant complex)
TargetCoagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor
Information of corresponding available drug in the market
Brand NameNovoSeven
CompanyNovo Nordisk
Brand DiscriptionNovoSeven is recombinant human coagulation Factor VIIa, intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven (coagulation factor viia recombinant) is a vitamin K-dependent glycoprotein consisting of 4
Prescribed forFor treatment and prevention of bleeding in surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response
Chemical NameN.A.
FormulationEach vial contains approximately 0. 6 mg/mL NovoSeven (coagulation factor viia recombinant) (corresponding to 600 _g/mL). The reconstituted vials have a pH of approximately 5. 5 in sodium chloride (3 mg/mL), calcium chloride dihydrate (1. 5 mg/mL), glycyl
Physcial AppearnceSterile, white lyophilized powder
Route of AdministrationInjection
Recommended DosageFor bleeding episodes, the recommended dose of NovoSeven (coagulation factor viia (recombinant)) for hemophilia A or B patients with inhibitors is 90 _g/kg given every two hours by bolus infusion until hemostasis is achieved, or until thehemostasis has been acheived.
ContraindicationHypersensitivity
Side EffectsRash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; bleeding at the injection site; bloody stools; calf or stomach pain, tenderness, or swelling; chest pain; confusion; dizziness; fainting; numbness.
Useful Linkhttp://www.novosevenrt.com
PubMed ID16418464
3-D StructureTh1032 (View) or (Download)